Carlsmed (CARL) Fundamentals 2026 — Revenue Analysis | SniperIQ
Carlsmed (CARL) is a US-listed Healthcare company in Medical - Devices with a market capitalization of
Carlsmed (CARL) has a market capitalization of approximately
Carlsmed's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Carlsmed runs a net profit margin of -58.8%, a gross margin of 75.9%, and an operating margin of -38.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Carlsmed reported revenue of $51M for fiscal year 2025, with net income of -
Carlsmed does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Carlsmed carries a debt-to-equity ratio of 0.19x and a current ratio of 11.88x, with a market beta of 3.66. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Carlsmed (CARL) the key facts are: market cap
Get Carlsmed's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.